This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
April 29, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced the appointment of Thomas W. D'Alonzo to the company's Board of Directors. Mr. D'Alonzo previously served on the BDSI Board of Directors from
August 2006 through
"We are very pleased to once again have Tom D'Alonzo as a member of our Board of Directors," said Dr. Frank E. O'Donnell, Jr., Executive Chairman of BDSI. "Tom's significant industry experience and leadership, which spans over more than 30 years in both large pharmaceutical and smaller biotechnology companies, will be a tremendous asset to BDSI."
Mark A. Sirgo, President and Chief Executive Officer of BDSI added, "Tom's extensive business and commercial experience and expertise will be particularly important as we continue to explore our options for the commercialization of BUNAVAIL for the treatment of opioid dependence, which includes commercializing the product on our own. We welcome Tom back and look forward to his contributions, which I am confident will assist BDSI in continuing to build value for patients and our stockholders."
Mr. D'Alonzo has held numerous high-level executive positions and board appointments within both large and specialty pharmaceutical companies. Mr. D'Alonzo has been a member of the Board of Directors at Salix Pharmaceuticals since
May 2000 and Chairman of the Board since
June 2010. Mr. D'Alonzo has previously served on the Board of Directors of Plexigen, Inc., DARA BioSciences, Inc. and Amarillo Biosciences, Inc.
Mr. D'Alonzo's extensive pharmaceutical industry background also includes a number of executive positions, including Chief Executive Officer at biotechnology companies DARA BioSciences, Inc. and GenVec, Inc. and President and Chief Operating Officer at Pharmaceutical Product Development (PPD), LLC, a global provider of discovery and development services to the pharmaceutical industry.